This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): 111-In-ABY-025, 68-Ga-ABY-025, Ga-ABY025, ABY 025, ABY025
Deal Structure: ABY-025 is a second generation HER2-binding molecular imaging agent, under development for the diagnosis of breast cancer.
Pink Sheet Global Pharma Guidance Tracker – August 2019
Additional information available to subscribers only: